Following FDA approval of the AspireSR® generator for the VNS Therapy® system in June 2015, more than a thousand patients with drug-resistant epilepsy across the United States have received this new treatment option. Many of these patients are experiencing benefits which have positively impacted their lives – and are sharing their stories during Epilepsy Awareness Month with the hope of encouraging others to seek new treatments for drug-resistant epilepsy. Numerous hospitals nationwide have begun providing the AspireSR device to patients with drug-resistant epilepsy – a condition that affects as many as one-third of people with epilepsy, causing them to have seizures in spite of treatment with antiepileptic medications.
The VNS Therapy system is a minimally invasive option in which a medical device is placed under the skin in the upper chest area during an outpatient procedure. The device sends mild electrical pulses through the vagus nerve to areas of the brain known to be associated with seizures. The new AspireSR generator takes the VNS Therapy technology a step further – detecting relative heart-rate increases that are often associated with seizures in people with epilepsy and providing responsive stimulation in an attempt to stop and shorten seizures and improve recovery.
To view the multimedia release go to:
http://www.multivu.com/players/English/7651751-livanova-aspiresr-treatment/
NEW YORK, NY (January 28, 2019) – Today, CancerCare celebrated its 75th anniversary by revealing a new campaign “If It Matters To You, It Matters To Us.” The campaign declares CancerCare’s commitment to holistic, patient-centered support services, and celebrates a legacy of comprehensive care for people living with cancer.
“A cancer diagnosis turns a person’s life upside down. Throughout many doctors’ visits, tests and treatments, people with cancer often feel like they’re perceived as a patient rather than a person,” said CancerCare CEO, Patricia Goldsmith. “For 75 years, CancerCare has championed the importance of addressing what matters most to patients and their families through free, direct services to help cope with the emotional, practical and financial challenges of a cancer diagnosis.”
To view the multimedia release go to:
https://www.multivu.com/players/English/8350251-cancercare-75th-anniversary-cancer-community/
Texas Oncology (http://www.texasoncology.com) is one of the nation’s leading cancer treatment networks, offering experienced physicians, advanced technologies, clinical research, and leading-edge treatments to patients in the fight against cancer.
With more than 300 physicians providing care at more than 100 sites of service throughout communities in Texas, New Mexico, and Oklahoma, Texas Oncology brings the power and resources of a world-class network to bear for cancer patients and their families every day. Celebrating its 25-year anniversary in 2011, Texas Oncology treats more Texans with cancer than any other provider in the state.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/texas-oncology/46947/
Changes in the treatment of pediatric cancer over recent decades have translated to a reduced risk of serious, long-term late health effects of cancer therapy. This is according to the latest analysis from the Childhood Cancer Survivor Study (CCSS), a National Cancer Institute-funded resource for late-effects research, led by investigators at St. Jude Children’s Research Hospital.
“This is the first comprehensive study to demonstrate how changes in treatments over time have impacted the occurrence of late effects experienced by childhood cancer survivors,” said Todd Gibson, Ph.D., assistant member of the Department of Epidemiology and Cancer Control at St. Jude. “We found the 15-year cumulative incidence of people reporting at least one severe health condition decreased from 12.7 percent among childhood cancer survivors diagnosed in the 1970s to 10.1 percent for those diagnosed in the 1980s to 8.8 percent in the 1990s–a statistically significant decline.”
To view the multimedia release go to:
https://www.multivu.com/players/English/7924756-st-jude-childhood-cancer-survivorship-asco-2017/
Solta Medical, Inc. (Nasdaq: SLTM), the global market leader in aesthetic skin treatments, today announced the launch of the Simply Smart Rewards Program for Clear + Brilliant laser treatments, the first-ever patient loyalty program in aesthetic laser skin resurfacing.
Clear + Brilliant and Clear + Brilliant Perméa treatments have been shown to help improve skin tone, texture and other subtle signs of aging. The precise laser energy has allowed most consumers to experience immediate and progressive results that last for months, but vary by age, skin condition and how they protect their skin. The treatment takes about 20 minutes, is safe for all skin types and is suitable for men and women.
To view Multimedia News Release, go to http://www.multivu.com/mnr/61178-solta-medical-launches-clear-brilliant-simply-smart-rewards-program
A new Economist Intelligence Unit (EIU) report titled The Silent Pandemic: Tackling Hepatitis C with Policy Innovation, made possible as a result of an educational grant from Janssen Pharmaceutica NV and published today, highlights the urgent need for countries around the world to develop strategies to tackle head-on the growing social and economic issues associated with Hepatitis C (HCV).
While the total number of infected individuals is unknown due to a lack of available data, the World Health Organization (WHO) estimates that approximately 150 million people globally are currently living with the blood-borne infectious disease, HCV. Of these, up to two thirds will develop chronic liver disease and one in five will develop cirrhosis. HCV is also the leading cause of liver transplantation worldwide and in the US the disease now accounts for more deaths than HIV.
To view Multimedia News Release, go to http://www.multivu.com/mnr/58671-janssen-silent-pandemic-hepatitis-c
For many women with frizzy, coarse, unruly hair, there’s no limit to what they would spend—or undergo—to achieve sleek, smooth, straight strands. With the advent of keratin-based salon straightening treatments, women are clamoring for the unprecedented smoothing benefits, spending upwards of $250 to experience the dramatic effects the services promise.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/johnfrieda/47819/
Express Scripts clinical innovations saved its clients $45 billion in 2018 and delivered a 25-year record low drug trend of just 0.4 percent across employer-sponsored plans, according to data released today in its annual Drug Trend Report, an authoritative analysis of drug spending in the U.S.
Express Scripts’ solutions for driving lower drug prices and fostering the use of lower-net-cost treatments are making medication more accessible for beneficiaries. Unit drug costs decreased in 2018 for employer-sponsored and Medicare plans, while utilization of medications rose.
To view the multimedia release go to:
https://www.multivu.com/players/English/8478051-express-scripts-2018-drug-trend-report/
The website www.MyPerfectDish.eu aims to help people with Parkinson’s, their relatives and caregivers in taking care of their nutritional requirements in order to help them enjoy tasty food that meets their dietary needs.
The website is endorsed by the European Parkinson’s Disease Association (EPDA) and sponsored by Zambon, and has been designed as an easy-to-use scientific information tool so people living with Parkinson’s can be confident that what they are reading is reliable.
“As the only European Parkinson’s umbrella organisation, the EPDA is very proud to endorse this project, which is based on solid scientific and medical grounds,” explains EPDA president Knut-Johan Onarheim. “A balanced and varied diet is important for everyone but it is even more important for people living with Parkinson’s disease because the right food intake can improve their quality of life as well as the effects of therapeutic treatments”.
“Zambon is very proud of having supported this project, which will help people with Parkinson’s and all those involved in the management of the disease. We are strongly committed to drive research and develop solutions to help patients in all their needs“. states Elena Zambon, President of Zambon.
To view the multimedia release go to:
http://www.multivu.com/players/uk/7864251-parkinsons-diet-online-resource/
Over 80% of Americans want to spend their last days at home, with friends and family. Yet, despite these desires, 75% of Americans will spend their last days in a hospital room. Many people will spend hours each day getting painful and often useless treatments and tests, and be asked to take dozens of debilitating drugs. For many, the cure is worse than the disease. This often has negative and lasting effects on family and friends who are often left with feelings of guilt and regret for years to come.
Hospice Support Fund is a 501(c)(3) non-profit organization dedicated to promoting end of life care at home rather than in a hospital so patients can spend their last days in dignity and peace, pain-free in familiar, comfortable surroundings with friends and family.
To view the multimedia release go to:
http://www.multivu.com/players/English/7785451-hospice-support-fund-end-of-life-care-psa/
The largest-ever morbi-mortality study of treatments for chronic heart failure has shown that adding the specific heart rate lowering agent Procoralan® (ivabradine) to standard therapy significantly reduces the risk of death and hospitalisation for heart failure.1 Results from this new study, SHIFT (Systolic Heart Failure Treatment with the If Inhibitor Ivabradine Trial), were presented today at the European Society of Cardiology1 in Stockholm and published in The Lancet.2
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/prne/shift/44195/
